Clinical trials
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric cancer or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,148 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Sarasota, FloridaAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06113016RecruitingPhase 2
Preventing frailty with fisetin and exercise in breast cancer survivors
This study tests whether adding a supplement called fisetin to an exercise program can help prevent frailty in women who have finished chemotherapy for early-stage breast cancer. If you are postmenopausal, have completed chemo within the last year, and can walk a certain distance, you may qualify.
Alhambra, CaliforniaAges Any age - NCT07405190RecruitingPhase 2
Ivonescimab with or without chemo for advanced NSCLC
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT06711211Recruiting
Digestive cancer registry study
This study collects information from patients with different types of digestive cancers to better understand these diseases and improve future care. It does not test a new treatment, but helps doctors learn more about digestive cancers over time.
Madrid, MadridAges 18 years+ - NCT07158021RecruitingPhase 2
Comparing two ovarian suppression drugs for breast cancer
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
Ann Arbor, MichiganAges 18 years+ - NCT07433283RecruitingPhase 1/Phase 2
Iron nanoparticle injection for advanced solid tumors
This trial tests a new treatment for advanced solid tumors that uses tiny iron particles guided by carbon nanoparticles, injected directly into the tumor. It may be an option if standard treatments have stopped working or aren't available, and you have a tumor that can be safely injected.
Beijing, Beijing MunicipalityAges 18–80 - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05595499RecruitingPhase 2
Fisetin for better walking and strength in breast cancer survivors
This study tests whether fisetin (a natural compound) can improve physical function, like walking ability, in breast cancer survivors who feel frail. It may help strengthen muscles and improve daily activity after treatment.
Alhambra, CaliforniaAges Any age - NCT07144826RecruitingEarly Phase 1
Probiotic for Gut and Vaginal Health in Ovarian Cancer Chemotherapy
This trial tests whether taking a probiotic supplement can help balance the bacteria in your gut and vagina while you undergo chemotherapy for advanced ovarian cancer. It aims to see if this could improve your treatment experience or outcomes.
Columbus, OhioAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07443943RecruitingPhase 2
Potato starch supplement for joint pain from hormone therapy
This trial studies whether a dietary supplement made from resistant potato starch can help reduce joint and muscle pain in people who are about to start aromatase inhibitor therapy for breast cancer or high risk. You take the supplement daily and report how you feel over 24 weeks.
Ann Arbor, MichiganAges Any age - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+ - NCT06607458RecruitingPhase 2
Liver-focused chemo for metastatic colorectal cancer
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06764095RecruitingPhase 4
Drug combo before bladder or ureter surgery for advanced cancer
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Rochester, MinnesotaAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT06840704RecruitingPhase 3
Can immunonutrition reduce esophagitis during lung cancer radiation?
This trial tests if a special nutritional supplement (immunonutrition) can lower the risk of severe throat and chest irritation (esophagitis) caused by radiation therapy for lung cancer. You may qualify if you are about to start chest radiation and can eat normally.
Changsha, HunanAges 18 years+
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 1,148 recruiting gastric cancer or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.